KUALA LUMPUR, Nov 10 (Bernama) — Malaysia clinical research fraternity accomplished global recognition, when several of the international clinical studies participated by Malaysian oncologists were featured in the recently held European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. The ESMO Congress is a highly influential oncology platform that’s held annually, presenting latest data in oncology research and clinical management as well as sharing ground-breaking cancer treatments.
Key highlights in the congress were the proffered paper presentations during presidential sessions, among which Dr Muthukkumaran Thiagarajan (Clinical Oncologist from Hospital Kuala Lumpur) and Dr Adlinda Alip (Clinical Oncologist from University Malaya Medical Centre) were named the co-authors in two Non-Small Cell Lung Cancer (NSCLC) studies. Both studies presented superior results of the respective trial treatment, establishing these treatments as first-in-line treatment for NSCLC with specific mutations. In addition, at least two other studies involving Malaysian oncologists were presented during the oral presentation sessions held in ESMO Congress 2023.